AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Gina Ford, RPh to the role of Vice President of Commercial Strategy. Ms. Ford has worked with AcelRx as a consultant from 2013 to the present and has been instrumental in the development of a commercial strategy for Zalviso™ (sufentanil sublingual tablet system), a drug-device combination product now approved in Europe for the management of acute moderate-to-severe post-operative pain in adult patients. As VP Commercial Strategy, Ms. Ford will be responsible for developing the commercial plan for ARX-04 in the U.S., Europe and other geographies.

“Gina’s work with AcelRx to date, especially the market research she has conducted to help us better understand the global opportunities for Zalviso and ARX-04, has been invaluable,” stated Timothy E. Morris, chief financial officer ofAcelRx Pharmaceuticals. “As we advance ARX-04 into the second planned Phase 3 study, SAP302, in the emergency room setting, and prepare our regulatory filings in the U.S. and the E.U., we will be relying heavily on Gina’s expertise in market access, pricing, payor relations and branding to promote a successful launch, should ARX-04 be approved. We look forward to welcoming her full-time to our team during this exciting period in the Company’s evolution.”

Before joining the AcelRx management team, Ms. Ford was principal and sole proprietor of One Joule, a commercial strategy consulting company. During her tenure at One Joule, Ms. Ford provided clients, including AcelRx, with strategic advice on commercial, marketing and life-cycle management strategy. She also led launch preparations, including forecasting, market sizing, launch training and communications, and sales territory alignment for One Joule clients. Before founding One Joule, Ms. Ford was president of Accesia, a wholly owned subsidiary of Patient Services, Inc., and held several leadership roles at Ipsen, a global pharmaceutical company focusing on neurology, endocrinology and urology-oncology. Ms. Ford received a Bachelor of Science in pharmacy from Southwestern Oklahoma State University and a Master of Business Administration from Capella University. (Original Source)

Shares of Acelrx Pharmaceuticals closed yesterday at $3.05. ACRX has a 1-year high of $9.32 and a 1-year low of $2.92. The stock’s 50-day moving average is $4.01 and its 200-day moving average is $4.01.

On the ratings front, Acelrx has been the subject of a number of recent research reports. In a report issued on September 22, Roth Capital analyst Michael Higgins reiterated a Buy rating on ACRX, with a price target of $8.50, which implies an upside of 178.7% from current levels. Separately, on September 14, H.C. Wainwright’s Ed Arce reiterated a Buy rating on the stock and has a price target of $8.50.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Michael Higgins and Ed Arce have a total average return of 7.4% and 18.5% respectively. Higgins has a success rate of 56.5% and is ranked #1075 out of 3755 analysts, while Arce has a success rate of 36.7% and is ranked #262.

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in thedevelopment and commercialization of therapies for the treatment of acute pain.